Weekly Recap: INLIGHT Phase 2a for WVE-007 and Dr. Vnuk 375k-share option

Wave Life Sciences Inc (NASDAQ:WVE) launched a Phase 2a INLIGHT trial testing WVE-007 alone and with tirzepatide for weight- and muscle-loss in adults with obesity, while granting Dr. Vnuk an option for 375,000 WVE shares at $4.25 each vesting over four years.Previous Week RecapThis is an AI-genera…